| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84a2ea4c841c6bb589df08b0666098b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dbeab7c420445e258c1383878607491
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0b5eaa680f158ec81ab4c535ef97bdd |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e4c8fd33bab5ec562ae8d3e0ab4d80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8062819d551868eaf38aaf83b3451bbb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be168982c77916c4c9a86a733a636271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9948b7326b49eb16930e753b8ebce0e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9eed38434ff4d7a25608e12ad120f5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62be242ca988544423648de51d40d7ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b38b27b438e8387d1789246e0f698ec5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bcffe6c52593abbff07dc0f83a685e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dda738ae5da8e15b65f53e6afb06951 |
| publicationDate |
2010-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-2008697-A3 |
| titleOfInvention |
Combinations of monoclonal antibodies or a Fab fragment thereof for use as a medicament and a pharmaceutical composition comprising such antibodies or Fab fragments thereof |
| abstract |
Combination of monoclonal antibodies against growth factors of IGF-2 and BMP-4 or a Fab fragment thereof for use as a medicament, particularly for use in the treatment of cancer, preferably squamous head and neck cancer. The invention also includes a pharmaceutical composition comprising monoclonal antibodies against IGF-2 and BMP-4 and optionally also a cytostatic. The monoclonal antibodies are preferably humanized and can be further coupled to carriers of soluble polymer. |
| priorityDate |
2008-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |